Servier SA must like what it’s seen so far from MacroGenics Inc. The French pharma originally partnered with the antibody developer in late 2011 and then announced a new deal on Sept. 20. Under the latest deal, Servier has taken an option on three more programs from MacroGenics, all derived from the start-up’s bi-specific antibody platform.
Servier paid Rockville, MD-based MacroGenics $20 million up-front in the new deal, matching the initial component of the two companies’...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?